Gene Therapy for SMA-- Full technical analysis #VolatilityWatch

25 de mai. de 2019

• RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA).
  
• (SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe.
  
• It is the number one genetic cause of death for infants.
  
• According to a company filling, price tag for treatment is $2.1 million.
  
• Product is called Zolgensma
  

Congrats to RGNX and Novartis for the huge accomplishment!

I am putting this on #VolatilityWatch

Come Join our Biotech trading team!

Twitter: VolatilityWatch
StockTwits: MS_Money_Moves

Disclaimer: I currently do not own any position in RGNX. This is not advice to buy or sell, It is for educational purposes. Please do your homework before investing.